NantKwest Inc. (NK) and Vital Therapies Inc. (NASDAQ:VTL) Comparing side by side

NantKwest Inc. (NASDAQ:NK) and Vital Therapies Inc. (NASDAQ:VTL), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NantKwest Inc. N/A 1843.53 103.37M -0.65 0.00
Vital Therapies Inc. N/A 0.00 41.48M -1.27 0.00

Table 1 demonstrates NantKwest Inc. and Vital Therapies Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
NantKwest Inc. 0.00% -54.2% -46.3%
Vital Therapies Inc. 0.00% -167.4% -132.2%

Volatility & Risk

NantKwest Inc.’s current beta is 2.72 and it happens to be 172.00% more volatile than S&P 500. Competitively, Vital Therapies Inc. is 255.00% more volatile than S&P 500, because of the 3.55 beta.

Liquidity

NantKwest Inc.’s Current Ratio and Quick Ratio are 3.3 and 3.3 respectively. The Current Ratio and Quick Ratio of its competitor Vital Therapies Inc. are 3.3 and 3.3 respectively. therefore has a better chance of paying off short and long-term obligations compared to .

Analyst Recommendations

NantKwest Inc. and Vital Therapies Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NantKwest Inc. 0 1 0 2.00
Vital Therapies Inc. 0 0 0 0.00

The average price target of NantKwest Inc. is $2, with potential upside of 65.29%.

Institutional and Insider Ownership

NantKwest Inc. and Vital Therapies Inc. has shares owned by institutional investors as follows: 11.5% and 15.7%. NantKwest Inc.’s share owned by insiders are 65.43%. Competitively, 0.1% are Vital Therapies Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NantKwest Inc. 0.85% 10.19% -31.61% -61.11% -72.95% 2.59%
Vital Therapies Inc. 13.49% 7.82% -23.68% -97.3% -95.65% 27.32%

For the past year NantKwest Inc. has weaker performance than Vital Therapies Inc.

Summary

On 5 of the 7 factors NantKwest Inc. beats Vital Therapies Inc.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patientÂ’s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.